Close Menu

NEW YORK – Becton Dickinson said this week that it is seeing increasing uptake of  its new high-throughput molecular diagnostics instrument, the BD Cor, and assay for human papillomavirus genotyping, as well as of its original BD Max molecular instrument.

BD also said that it is experiencing sustained growth in China in general that it expects to continue despite shifting sands in US-China trade relations.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.